SOHO 2023 | Improvements and remaining challenges in treating R/R MCL after failure of BTK inhibitors
Michael Wang
• 6 Sep 2023
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses how CAR-T therapies and bispecific antibodies have overcome the challenge of treating patients with mantle cell lymphoma (MCL) who fail treatment with BTK inhibitors. Prof. Wang highlights the remaining unmet need of patients who subsequently fail immunotherapy. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
